By Joe Gorelick, MSN, FNP-C What’s new in the treatment of advanced melanoma? A second-generation melanoma vaccine appears to provide greater benefit than a first-generation vaccine, according to data from UVA Cancer Center, where the new vaccine was developed. The...
A $3.2 million grant from the NIH will support the creation of Melanoma Resistance Evolution Atlas (MREA). Ultimately, researchers hope to develop novel approaches to prevention and treatment of resistant melanomas. Led by Dr. Roger Lo, professor of medicine and...
— UPDATE: NDA Approvals for 2023 now stand at 54, with a fourth dermatologic indication approved! Filsuvez® (birch triterpenes) topical gel from Chiesi Global Rare Diseases has received FDA approval for the treatment of partial thickness wounds in patients 6...
By Joe Gorelick, MSN, FNP-C An investigational anti-tumor compound may have efficacy against melanoma and squamous cell carcinoma (SCC), as well as lung cancer, researchers say. Plixorafenib (also called PLX8394) is currently in phase 2 clinical trials for melanoma...
By Joe Gorelick, MSN, FNP-C Rates of melanoma and non-melanoma skin cancer continue to rise, even as sunscreen use increases. According to researchers from McGill University, this “sunscreen paradox” reflects the tendency of individuals to view sunscreen use as...
Having declined slightly in the early 2000s, the rate of new female breast cancer cases has ticked up each year from 2014 to 2019, according to the CDC. And while the number of breast cancer deaths has been relatively stable for the last 2 decades, the death rate has...